OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. O’Malley on the Activity of Mirvetuximab Soravtansine in Ovarian Cancer

July 21st 2020

David O'Malley, MD, discusses the activity of ​the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.

Dr. Chandra on the Incidence of Targetable Mutations in Melanoma

July 21st 2020

Sunandana Chandra, MD, MS, discusses the incidence of targetable mutations in melanoma.

Dr. Leslie on the Role of BTK Inhibitors in Relapsed/Refractory MCL

July 20th 2020

Lori A. Leslie, MD, discusses the role of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Costello on Sequencing Challenges in Multiple Myeloma

July 20th 2020

Caitlin Costello, MD, discusses sequencing challenges in multiple myeloma.

Dr. Roué on ​the Next Steps ​With TG-1701 in MCL

July 20th 2020

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPC

July 20th 2020

Neal D. Shore, MD, FACS, discusses the safety and tolerability benefits of darolutamide in men with nonmetastatic castration resistant prostate cancer.

Dr. Al-Sawaf on Continual MRD Assessment ​After Venetoclax/Obinutuzumab in CLL

July 20th 2020

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.

Dr. Davids on the Design of the Phase 3 UNITY Trials in Relapsed/Refractory CLL and MCL

July 17th 2020

Matthew S. Davids, MD, MMSc, discusses the design of the UNITY trials in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Ahn on Advancing Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.

Dr. Moore on Unmet Clinical Needs in Platinum-Resistant Ovarian Cancer

July 17th 2020

Kathleen Moore, MD, discusses the unmet clinical needs in platinum-resistant ovarian cancer.

Dr. Gafita on the Rationale to Evaluate 177Lu-PSMA-617 in mCRPC

July 17th 2020

Andrei Gafita, MD, discusses the rationale to evaluate lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.

Dr. Shaughnessy on Available CAR T-Cell Therapies in R/R Hematologic Malignancies

July 17th 2020

Paul J. Shaughnessy, MD, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

Dr. Mesa on Recent Data With Momelotinib in MPNs and Myelofibrosis

July 17th 2020

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses recent data with momelotinib in myelofibrosis.

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

July 17th 2020

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

Dr. Kumar on the Rationale for the ENDURANCE Trial in Multiple Myeloma

July 17th 2020

Shaji K. Kumar, MD, discusses the rationale for conducting the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Dr. Abou-Alfa on Remaining Questions With Infigratinib in FGFR2+ Cholangiocarcinoma

July 16th 2020

Ghassan K. Abou-Alfa, MD, discusses the questions that remain with infigratinib in advanced cholangiocarcinoma with FGFR2 gene fusions/translocations.

Dr. Bach on Examining ctDNA in CRC

July 16th 2020

Sander Bach, MD, PhD, discusses research examining circulating tumor DNA in colorectal cancer.

Dr. Czerniecki on the Importance of Multidisciplinary Efforts for Breast Cancer Brain/CNS Metastases

July 16th 2020

Brian Czerniecki, MD, PhD, discusses the importance of utilizing a multidisciplinary effort to treat patients with breast cancer who develop brain or central nervous system metastases.

Dr. Daver on the Advancing Treatment Landscape in AML

July 16th 2020

Naval G. Daver, MD, discusses the advancing treatment landscape in both acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. Gilbert on the Safety Profile of Mirvetuximab Soravtansine/Bevacizumab in Ovarian Cancer

July 16th 2020

Lucy Gilbert, MD, MSc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

NEXT PAGE
PREVIOUS PAGE